Hypophosphatemia foscarnet

Foscarnet 40 mg/kg IV q8—12hours x 2-3 wkor until clinical resolution is attained Renal insufficiency, metabolic disturbances, hypophosphatemia... 

Mineral and electrolyte imbalances Foscarnet has been associated with changes in serum electrolytes including hypocalcemia (15%), hypophosphatemia (8%) and hyperphosphatemia (6%), hypomagnesemia (15%), and hypokalemia (16%). Foscarnet is associated with a transient, dose-related decrease in ionized serum calcium, which may not be reflected in total serum calcium. 

Foscarnet competitively inhibits Na -Pj cotransport in animal and human kidney proximal tubule brush border membrane vesicles, reversibly inhibiting sodium-dependent phosphate transport [48, 49]. Renal cortical Na-K-ATPase and alkaline phosphatase activity are not inhibited by foscarnet, nor is proline, glucose, succinate, or Na" transport [48,49]. Foscarnet induces isolated phosphaturia without hypophosphatemia in thyroparathyroidectomized rats maintained on a low phosphorus diet, without affecting glomerular filtration rate, urinary adenosine 3 5 -cyclic monophosphate (cAMP) activity, or urinary calcium, sodium or potassium excretion [48,50]. Sodium-Pj cotransport in brush border membrane vesicles from human renal cortex was reported to be even more sensitive to inhibition by foscarnet than in rat renal brush border membrane vesicles [49]. 

Foscarnet 40-80 mgIVq. 8 hr 85% 40-20 mg q. 8-24 hr, according to Nephrotoxic, neurotoxic adverse effects are hypocaicemia, hypophosphatemia, hvoomaqnesemia.and hvookaiemia Dose after dialysis Dose for GFR<10 ml/min Dose for GFR 10-50 ml/min... 

Foscarnet 40-80 mg IV qShrs 85% 40-20 mg q8-24 hrs according to CICr Nephrotoxic, neurotoxic, hypocalcemia, hypophosphatemia, hypomagnesemia and hypokalemia... 

---